Asahi Kasei Group’s medical devices manufacturer ZOLL Medical has signed a strategic multi-year research and development (R&D) collaboration agreement with technology and soft electronics firm Myant for ZOLL LifeVest wearable defibrillator.

Under the terms of the agreement, the firms will jointly develop technologies to be utilised in future generations of the wearable defibrillator.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The LifeVest device is developed for patients who are at risk of sudden cardiac death (SCD) to provide protection during their changing condition and when permanent SCD risk has not been determined.

It is designed to monitor heart rate and upon detection of a life-threatening heart rhythm, the device delivers a treatment shock to restore normal rhythm.

The firms intend to combine the benefits of advanced materials science, machines, yarn with nanotechnology and manufacturing.

“It is designed to monitor heart rate and upon detection of a life-threatening heart rhythm, the device delivers a treatment shock to restore normal rhythm.”

ZOLL LifeVest president Jason Whiting said: “This collaboration with Myant aligns with ZOLL’s longstanding commitment to research and development with the goal of improving patient outcomes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are excited to combine efforts with Myant and leverage their strong R&D capabilities, advanced manufacturing, and broad research capabilities from its Centres for Excellence in Canada and the US.”

The LifeVest wearable defibrillator is indicated for a variety of patient conditions such as myocardial infarction, coronary revascularisation, cardiomyopathy, or congestive heart failure.

Established in 2010, Myant creates a computing textile platform to sense, record, analyse and respond, while it ambiently interfaces with humans and artificial intelligence (AI) through textiles.